EVO ICL: Latest Implantable Lens Technology
Understanding EVO ICL Technology
The EVO ICL (Implantable Collamer Lens) represents the newest generation of implantable lens technology for vision correction, offering a powerful alternative for patients who may not be ideal candidates for laser eye surgery. Approved by the FDA in 2022, the EVO ICL corrects moderate to high myopia (nearsightedness) and astigmatism by placing a biocompatible lens inside the eye, leaving the cornea completely untouched.
At Fairfield County Laser Vision, our refractive surgeon uses advanced diagnostic and surgical technology to evaluate whether EVO ICL is the right path toward clearer vision for patients throughout the greater NY/CT region. This page explains how the EVO ICL works, what makes it different from earlier implantable lenses, and what you can expect from the procedure and recovery.
What Is the EVO ICL
Collamer is uniquely designed to work in harmony with the eye's natural environment. Because it contains collagen, the lens is recognized by the body as a natural material, which reduces inflammation and keeps the lens clear over time. Collamer also provides built-in ultraviolet protection, filtering harmful UV rays before they reach the natural lens and retina.
One of the most important advances in the EVO ICL compared to earlier implantable lens models is its central port, called the KS-Aquaport. This small opening in the center of the lens allows the eye's natural fluid (aqueous humor) to flow freely between the front and back of the lens. The central port eliminates the need for a preoperative laser peripheral iridotomy, a procedure previously required to prevent fluid buildup and pressure spikes.
Although the EVO ICL is sometimes described as an 'implantable contact lens,' it functions very differently from the contacts you wear on the surface of your eye. The EVO ICL is placed behind the iris and in front of your natural lens, in an area called the posterior chamber. Once positioned, you cannot feel it, and it requires no daily handling, cleaning, or replacement.
How the EVO ICL Procedure Works
Before surgery, you will undergo a comprehensive eye examination that includes corneal topography, anterior chamber depth measurement, endothelial cell count, and a detailed refraction. These measurements help determine your exact lens size and power. The lens is then custom-ordered to match the unique dimensions of your eye.
On the day of the procedure, numbing eye drops are applied so you remain comfortable throughout. A tiny micro-incision, typically 2.8 to 3.0 millimeters, is made at the edge of the cornea. The folded EVO ICL is gently inserted through this incision and positioned behind the iris, where it unfolds into place. No stitches are needed because the incision is self-sealing. Most patients notice an improvement in vision within hours of the procedure.
After surgery, you will rest briefly in the recovery area while your eye pressure is checked. You will need someone to drive you home. Prescribed eye drops, typically including an antibiotic and anti-inflammatory medication, are used for several weeks to support healing.
Advantages of EVO ICL Technology
The EVO ICL can correct myopia ranging from -3.0 to -20.0 diopters and astigmatism from 1.0 to 4.0 diopters. This makes it an effective option for patients with prescriptions that fall outside the treatable range for LASIK eye surgery. Patients with very high nearsightedness who have been told they are not candidates for laser vision correction may find that the EVO ICL provides an excellent alternative.
Because the EVO ICL is placed inside the eye rather than reshaping the cornea, no corneal tissue is permanently removed during the procedure. This is particularly beneficial for patients with thin or irregular corneas who are not suitable candidates for laser-based procedures. Preserving the cornea's natural structure also means that future surgical options remain fully available.
The EVO ICL is designed to be a long-term solution, but it can be removed or exchanged if a patient's needs change over time. This reversibility provides flexibility that permanent corneal procedures cannot offer. Additionally, because the EVO ICL does not alter the cornea, it avoids disrupting the corneal nerves responsible for tear production, reducing the risk of post-surgical dry eye.
Clinical data from FDA trials show that 98.5% of EVO ICL patients achieved the same or better vision than they had with glasses or contact lenses at six months after surgery. According to a literature review in the Journal of Refractive Surgery covering 95 studies, 92.6 percent of LASIK patients reported being satisfied with their surgery, and ICL satisfaction rates are similarly high (Susanna et al., 2025). The Collamer material provides sharp optics with minimal higher-order aberrations.
Who Is a Good Candidate for EVO ICL
The best candidates for EVO ICL are typically between the ages of 21 and 45 with stable myopia in the range of -3.0 to -20.0 diopters. Candidates should have a sufficient anterior chamber depth (the space between the cornea and the natural lens) to accommodate the implant safely. A stable prescription for at least one year prior to surgery is also important to ensure predictable results.
Patients who have been told they are not good candidates for LASIK or PRK due to thin corneas, high prescriptions, or chronic dry eye may be excellent candidates for the EVO ICL. The implantable collamer lens approach bypasses corneal limitations entirely, expanding access to surgical vision correction for these individuals.
Certain conditions can affect candidacy for EVO ICL implantation. These include a shallow anterior chamber depth that cannot safely accommodate the lens, moderate to advanced cataracts, uncontrolled glaucoma or a history of significant intraocular inflammation, and endothelial cell counts below a safe threshold for implantation.
It is important to understand that the EVO ICL corrects distance vision but does not address presbyopia, the age-related loss of near focusing ability. Patients over 40 who receive an EVO ICL may still need reading glasses for close-up tasks. Our refractive surgeon discusses these expectations in detail during your consultation.
Frequently Asked Questions
The EVO ICL is designed to remain in the eye indefinitely without degrading. The Collamer material does not break down over time, and the lens does not require replacement on a set schedule. If your vision needs change significantly in the future, the lens can be exchanged or removed.
Most patients notice significantly improved vision within the first day after surgery. Light activities such as walking can typically be resumed within a day or two. You should avoid swimming, heavy lifting, and contact sports for at least two weeks. Vision continues to stabilize over the first few weeks.
The procedure itself is not painful. Numbing eye drops are applied before surgery to keep you comfortable. Some patients report mild pressure or a sensation of water in the eye during the procedure, but significant pain is uncommon. Mild soreness and light sensitivity during the first day or two typically resolve quickly.
LASIK reshapes the cornea permanently using a laser, while the EVO ICL leaves the cornea untouched and places a lens inside the eye. LASIK is generally well suited for mild to moderate prescriptions, while the EVO ICL can correct much higher levels of myopia. The EVO ICL also carries a lower risk of dry eye and offers the advantage of reversibility.
Modern EVO ICL design and precise sizing have significantly reduced the risk of cataract formation compared to earlier implantable lens models. Proper preoperative measurements ensure adequate clearance between the ICL and your natural lens, which is the key factor in preventing lens opacity. Studies show the risk is very low with current-generation EVO ICL technology.
For patients exploring long-term outcomes of refractive surgery, the EVO ICL can represent a lasting investment in visual freedom. The lens is designed to provide stable vision correction for decades, and the reversible nature of the procedure means options remain open if circumstances change.
Take the Next Step Toward Clearer Vision
If you have been told you are not a candidate for laser vision correction, or if you are looking for a reversible approach to treating high myopia or astigmatism, the EVO ICL may be the right solution. Our fellowship-trained refractive surgeon at Fairfield County Laser Vision has the expertise and advanced technology to evaluate your eyes thoroughly.
We welcome you to schedule a consultation to learn whether the EVO ICL is a good fit for your vision goals and your eyes.
What our Patients say
4.8
Reviews
(3,408)